Vergent Bioscience, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2016-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.vergentbio.com
Phase 2B Safety and Efficacy Study of VGT-309 in Subjects With Cancer in the Lung.
Phase 2
Recruiting
- Conditions
- Lung CancerLung Metastases
- Interventions
- Drug: VGT-309
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Vergent Bioscience, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT06145048
- Locations
- 🇺🇸
Orlando Health Cancer Institute, Orlando, Florida, United States
🇦🇺St. Vincent's Hospital, Melbourne, Victoria, Australia
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Phase 2 Study of VGT-309 in Lung Cancer
Phase 2
Completed
- Conditions
- Lung Cancer
- Interventions
- Drug: VGT-309
- First Posted Date
- 2022-06-01
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Vergent Bioscience, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT05400226
- Locations
- 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
© Copyright 2025. All Rights Reserved by MedPath